Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LIPA | P38571 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7511817 | 0.88 | TLR4 (0.35) | CYP1A2LIPA | |
| SCHEMBL10706384 | 0.83 | CYP1A2 (0.64) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL10486374 | 0.83 | CYP1A2 (0.64) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL10486366 | 0.83 | CYP1A2 (0.64) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL17614847 | 0.83 | CYP1A2 (0.45) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL17614829 | 0.82 | LIPA (0.34) | LIPA | |
| SCHEMBL17147739 | 0.81 | CYP1A2 (0.42) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL13614977 | 0.81 | CYP1A2 (0.42) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL9336831 | 0.80 | CYP1A2 (0.42) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL9336835 | 0.80 | CYP1A2 (0.42) | CYP1A2LMNAMAPK1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580652-B2 | Liquid crystal compound, liquid crystal composition including the same and liquid crystal display including the liquid crystal composition | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-28 | — | — | US | disclosed |
| US-9580652-B2 | Liquid crystal compound, liquid crystal composition including the same and liquid crystal display including the liquid crystal composition | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-28 | — | — | US | disclosed |
| US-20160083653-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME AND LIQUID CRYSTAL DISPLAY INCLUDING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY COMPRISING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083653-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME AND LIQUID CRYSTAL DISPLAY INCLUDING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY COMPRISING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY COMPRISING THE LIQUID CRYSTAL COMPOSITION | NAP1L1, SLFN12, RCC2 | CYP1A2 660/4885LMNA 1287/4885MAPK1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.